Free Trial
→ I'm handing you this one free (From Behind the Markets) (Ad)tc pixel
NASDAQ:NGNE

Neurogene Q3 2026 Earnings Results & Report

Neurogene logo
$25.34 -0.66 (-2.54%)
As of 02:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Neurogene beat analyst earnings expectations in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$1.05 versus the -$1.36 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Neurogene EPS Results

Actual EPS
-$1.05
Consensus EPS
-$1.36
Beat/Miss
Beat by +$0.31
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Neurogene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Neurogene's Q3 2026 Press ReleasePress Release
(8-K)
Neurogene's Q3 2026 Quarterly reportQuarterly report
(10-Q)

Neurogene Q3 2026 Earnings FAQ

Neurogene (NASDAQ:NGNE) reported earnings of -$1.05 per share for Q3 2026, beating the consensus estimate of -$1.36. The report was announced on Monday, November 9, 2026.

Neurogene Earnings Headlines

Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates
November 9 at 8:00 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261109901272/en/Neurogene-Reports-Third-Quarter-2026-Financial-Results-and-Highlights-Recent-Updates/
Neurogene (NASDAQ:NGNE) and Ultragenyx Pharmaceutical (NASDAQ:RARE) Head to Head Survey
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31180289
Why Iran May Only Be the First Move
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen. No cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.tc pixel
November 10 at 1:00 AM  |  Behind the Markets (Ad)
Neurogene to Participate in Upcoming Investor Conferences
November 3, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261103409653/en/Neurogene-to-Participate-in-Upcoming-Investor-Conferences/
Neurogene (NASDAQ:NGNE) Stock Rating Reaffirmed as Buy by HC Wainwright
October 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31166982
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
October 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261027401714/en/neurogene-presents-new-data-at-esgct-congress-that-reinforce-key-differentiators-of-ngn-401-gene-therapy-for-rett-syndrome/
See More Neurogene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neurogene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neurogene and other key companies, straight to your email.

About Neurogene

Neurogene (NASDAQ:NGNE) (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare neurological diseases. The company designs gene therapies intended to address the underlying genetic causes of disorders for which treatment options are limited or unavailable.

Neurogene’s lead program is NGN-401, an investigational gene therapy being developed for Rett syndrome, a rare neurodevelopmental disorder. The company is also advancing NGN-101 for CLN5 Batten disease, a form of neuronal ceroid lipofuscinosis. These programs use Neurogene’s proprietary EXACT technology, which is designed to help regulate therapeutic gene expression and support the development of potentially more effective gene therapies.

Neurogene was founded in 2018 and is based in New York. As a clinical-stage company, its activities primarily involve research, preclinical development and clinical testing of its gene therapy candidates. The company’s programs are intended for patients with rare neurological conditions in markets where applicable regulatory approvals may ultimately be obtained.

View Neurogene Profile
Earnings Tools